Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
Sweden’s Proposed Patents Act
On 11 April 2024, the Swedish Council on Legislation was presented with a new Swedish Patents Act proposal. The
CNIPA’s Regulations on Collective and Certification Trademarks: keypoints highlighted
The regulations contain 28 provisions across several critical topics Registrants of collective and certification marks must implement several acts
Balancing Innovation and Regulation: Comparing China’s AI Regulations with the EU AI Act
The recent passing of the EU AI Act presents an opportunity to conduct a comparative law analysis against China’s